Pharmacology, Toxicology and Pharmaceutical Science
Attention Deficit Disorder
100%
Atomoxetine
69%
Placebo
44%
Fluoxetine
21%
Symptom
20%
Clinical Trial
13%
Ebola Virus Disease
12%
Pharmacotherapy
12%
Psychopharmacology
10%
Placebo-Controlled Study
10%
Antidepressant
10%
Infectious Agent
10%
Adverse Event
9%
Major Depression
9%
Infection
9%
Combination Therapy
8%
Tolerability
8%
Disease
7%
SARS Coronavirus
7%
Remission
7%
Methylphenidate
7%
Controlled Clinical Trial
7%
Open-Label Trial
7%
Pandemic
7%
Clinical Research
7%
Selective Serotonin Reuptake Inhibitor
6%
Randomized Controlled Trial
5%
DSM-IV
5%
Medicine and Dentistry
Attention Deficit Disorder
30%
Virus Infection
26%
Ebolavirus
24%
Biocontainment
17%
Atomoxetine
16%
COVID-19
14%
Symptom
12%
Adolescent
11%
Pediatrics
11%
Pathogen
10%
Convergence Insufficiency
10%
Placebo
10%
Public Health
9%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Patient Care
7%
Quality of Life
7%
Epidemic
7%
Preschooler
7%
Disease
6%
Infection
5%
Patient with Attention Deficit Hyperactivity Disorder
5%
Respiratory Tract Infection
5%
Controlled Clinical Trial
5%
Keyphrases
Attention Deficit Hyperactivity Disorder
42%
Atomoxetine
36%
Placebo
14%
Adolescents with Depression
13%
Ebola Virus Disease
13%
Depression Study
12%
Children with Attention Deficit
10%
Cognitive Behavioral Therapy
9%
Fluoxetine
9%
Major Depressive Disorder
8%
Pharmacotherapy
8%
Depressed Adolescents
7%
Preschoolers
7%
Adolescent Depression
7%
United States
6%
Special Pathogens
5%
Ebola
5%
Child Patients
5%